IV-01 Nicolas Frances A translational threshold model to assess exposure-driven QTc changes Thursday 15:00-16:30 |
IV-02 Ben Francis Using Stochastic Control Methods and Pharmacokinetics to Individualise Drug Therapy: A Case Study with the Enzyme Inhibitor Imatinib. Thursday 15:00-16:30 |
IV-03 Chris Franklin Practical Implications of Ontology and Global Standards for Model-based Data Analysis Thursday 15:00-16:30 |
IV-04 Nicolas Frey Short- and Long-Term Effects of Tocilizumab on Neutrophil Counts in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis Thursday 15:00-16:30 |
IV-05 Lena Friberg Myelosuppression as a Biomarker of Tumor Response in Docetaxel Treated Metastatic Breast Cancer Patients Thursday 15:00-16:30 |
IV-06 Anne-Kristina Mercier A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A Thursday 15:00-16:30 |
IV-07 Ludivine Fronton Relevance of Endogenous IgG Binding to FcRn in PBPK Models of Therapeutic mAbs Thursday 15:00-16:30 |
IV-08 Aline Fuchs Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools Thursday 15:00-16:30 |
IV-09 Samira Garonzik Development of PK/PD Models to describe Pharmacokinetics and Biomarker Responses for Dovitinib (TKI258) Thursday 15:00-16:30 |
IV-10 Peter Gennemark Experimental design based on mechanistic mathematical modeling of body composition and energy turnover Thursday 15:00-16:30 |
IV-11 Cecile Gerard Determination of the most influential sources of variability of tacrolimus trough blood levels in adult liver transplant patients: a bottom-up approach Thursday 15:00-16:30 |
IV-12 Massimiliano Germani Population pharmacokinetic analysis in healthy volunteers treated with different oral formulations of riluzole. Thursday 15:00-16:30 |
IV-13 Leonid Gibiansky Monoclonal Antibody-Drug Conjugates (ADC): TMDD Equations, Approximations, and Identifiability of Model Parameters Thursday 15:00-16:30 |
IV-14 Bill Gillespie From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer's Disease Thursday 15:00-16:30 |
IV-15 Pascal Girard Simultaneous Ocular Adverse Event and Treatment Discontinuation Model of Pimasertib Thursday 15:00-16:30 |
IV-16 Sophie Glatt A population pharmacokinetic analysis and pharmacokinetic/adverse events analysis of a sodium channel blocker in healthy subjects. Thursday 15:00-16:30 |
IV-17 Martin Gnanamuthu Johnson Title: Pharmacokinetic-Pharmacodynamic Modeling of the relationship between D2 receptor occupancy and Catalepsy in Rats: Predicting Extrapyramidal Side Effects in Humans Thursday 15:00-16:30 |
IV-18 Daniel Gonzalez Population Pharmacokinetics of Two Volatile Markers Used for Assessment of Definitive Adherence Thursday 15:00-16:30 |
IV-19 Linus Görlitz Physiological modeling of interindividual variability: PBPK-NLME vs. compartimental modeling Thursday 15:00-16:30 |
IV-20 Nathalie Gosselin Simultaneous Optimization of Sampling Strategies for Parent and Metabolite Data Taking into Account a Body Weight Distribution: Applications to Paediatric Studies Thursday 15:00-16:30 |
IV-21 Verena Gotta Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions Thursday 15:00-16:30 |
IV-22 Navin Goyal Kinetic-Pharmaco Dynamic (K-PD) Modeling of a Novel Oral 5-Lipoxigenase Activating Protein (FLAP) Inhibitor for Asthma and its Comparison with a PK-PD Approach Thursday 15:00-16:30 |
IV-23 Iztok Grabnar Enterohepatic Recirculation of Free and Conjugated Silybin Following Administration of a Chewing Gum with Milk Thistle Extract Thursday 15:00-16:30 |
IV-24 Joachim Grevel Response type modelling and clinical trial simulation. Thursday 15:00-16:30 |
IV-25 Zheng Guan Population PK/PD modeling to compare cannabinoid receptor antagonists in the THC challenge test Thursday 15:00-16:30 |
IV-26 Ivelina Gueorguieva Development Of Integrated Pharmacokinetic/Pharmacodynamic (PK/PD) Model For The Novel TGF- β Inhibitor LY2157299 Monohydrate: Preclinical To Phase II Thursday 15:00-16:30 |
IV-27 Monia Guidi Population Pharmacokinetics of Risperidone and 9-hydroxy-risperidone in psychiatric patients. Thursday 15:00-16:30 |
IV-28 Emma Hansson PKPD Modeling of Predictors for Side Effects and Overall Survival in Patients with Gastro Intestinal Stromal Tumor Treated with Sunitinib Thursday 15:00-16:30 |
IV-29 Eva Hanze Comparison of longitudinal data analysis to end of treatment data analysis when evaluating precision in dose-exposure-response in neuropathic pain studies. Thursday 15:00-16:30 |
IV-30 Lutz Harnisch Determining the Pharmacokinetic (PK) Profile of Sildenafil in One Month to One Year Old Pediatric Pulmonary Arterial Hypertension (PAH) Patients Using Interpolation of Two Population Pharmacokinetic Models of Sildenafil in PPHN population (3 to 10 Days Old) and in Pediatric PAH population (1 to 17 Years Old) Thursday 15:00-16:30 |
IV-31 Tomi Hendrayana Population pharmacokinetic (PK) model for fluorouracil (5-FU) accounting for irregularities in infusion rate Thursday 15:00-16:30 |
IV-32 Emilie Hénin A latent-variable model for Sorafenib-induced Hand-Foot Syndrome (HFS) in non-selected patients to predict toxicity kinetics according to sorafenib administrations Thursday 15:00-16:30 |
IV-33 Stefanie Hennig Pharmacokinetics of tobramycin do not differ in patients with and without cystic fibrosis Thursday 15:00-16:30 |
IV-34 Sarapee Hirankarn Pharmacokinetics Of High-Dose Methotrexate In Children With Cancer: A Mechanism Based Evalution Of Clearance Prediction Thursday 15:00-16:30 |
IV-35 Richard Höglund A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated P.falciparum malaria Thursday 15:00-16:30 |
IV-36 Nick Holford What is the between cycle variability in methotrexate clearance? Thursday 15:00-16:30 |
IV-37 Andrew Hooker The Kaplan-Meier Mean Covariate plot (KMMC): a new diagnostic for covariates in time-to-event models. Thursday 15:00-16:30 |
IV-38 Daniel Hovdal A mechanism-based population model for estimation of system parameters, vehicle effects and drug-induced body weight changes in diet induced obesity mice Thursday 15:00-16:30 |
IV-39 Xiao Hu Comparison of Tolerance Models for Neopterin Elevation Following Interferon beta-1a or PEGylated Interferon beta-1a treatment in Rhesus Monkeys Thursday 15:00-16:30 |
IV-40 An Hyungmi The Modified Bland-Altman Method to Measure Agreement with Repeated Measures Data using Random Effects Model Thursday 15:00-16:30 |
IV-41 Laura Iavarone A population PK model combined with PK/PD model for analysis of headache in clinical trials Thursday 15:00-16:30 |
IV-42 Vijay Ivaturi Individual Observation-Shrinkage Scaling of Residuals in a Generalized Least Square Type of Estimation in NONMEM Thursday 15:00-16:30 |
IV-43 Masoud Jamei Model-Based Prediction of Domperidone and Ketoconazole Interaction and its Impact on QTc Prolongation Thursday 15:00-16:30 |
IV-44 Candice Jamois Pharmacokinetic-Receptor Occupancy Modeling to support Phase 2 Dose Selection Thursday 15:00-16:30 |
IV-45 Alvaro Janda Optimization of pharmacokinetics and pharmacodynamics profiles by optimal control methods. Application to a triptorelin-testosterone PD model. Thursday 15:00-16:30 |
IV-46 Juliette Janson Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels in vivo. Thursday 15:00-16:30 |
IV-47 Roger Jelliffe An Improved Population Model Prior for Nonparametric Sequential Interacting Multiple Model (IMM) Bayesian Analysis. Thursday 15:00-16:30 |
IV-48 Lee Jongtae Population pharmacokinetic analysis of colistin in burn patients Thursday 15:00-16:30 |
IV-49 Amita Joshi A physiologically-based pharmacokinetic (PBPK) approach to evaluate differences in pharmacokinetics between healthy subjects and cancer patients Thursday 15:00-16:30 |
IV-50 Matts Kågedal Improved dose selection for PET occupancy studies Thursday 15:00-16:30 |
IV-51 Friederike Kanefendt Modeling Sunitinib and Biomarker Response as potential Predictors of Time to Progression in Patients with Metastatic Colorectal Cancer Thursday 15:00-16:30 |
IV-52 Helene Karcher Therapeutic drug monitoring : modeling to assess risk and benefit for a novel drug used in combination Thursday 15:00-16:30 |
IV-53 Tatiana Karelina Kinetic Model of Amyloid Beta Distribution and Allometric Scaling from Mouse to Monkey and Human Thursday 15:00-16:30 |
IV-54 Mats Karlsson A full model approach based on the covariance matrix of parameters and covariates Thursday 15:00-16:30 |
IV-55 Nastya Kassir A Modelling and Simulations Framework to Optimize Paediatric Studies and Facilitate Decision-Making Thursday 15:00-16:30 |
IV-56 Takayuki Katsube Characterization of Stepwise Covariate Model Building Combined with Cross-Validation Thursday 15:00-16:30 |
IV-57 David Khan In silico predictions of in vitro growth competition experiments between wild type and resistant mutants of E. coli MG1655 exposed to ciprofloxacin Thursday 15:00-16:30 |
IV-58 Frank Kloprogge Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda Thursday 15:00-16:30 |
IV-59 Magdalena Kozielska Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia Thursday 15:00-16:30 |
IV-60 Elke Krekels Top-Down Modeling Meets Bottom-Up Modeling: The Physiological and Physicochemical Basis for the Ontogeny of UGT2B7-Mediated Drug Glucuronidation. Thursday 15:00-16:30 |
IV-61 Anders Kristoffersson Robust optimal design of ciprofloxacin time-kill curve experiments with respect to autocorrelation Thursday 15:00-16:30 |
IV-62 Wojciech Krzyzanski Methods of Solving Rapid Binding Target-Mediated Drug Disposition Model for Two Drugs Competing for the Same Receptor Thursday 15:00-16:30 |
IV-63 Steve Kuan Population Pharmacokinetic (PK) Modelling of Bortezomib After Bolus Intravenous Injection in Cancer Patients Thursday 15:00-16:30 |
IV-64 Brigitte Lacroix A single population pharmacokinetic model for oral levetiracetam in various populations – dose investigation for Japanese children Thursday 15:00-16:30 |
IV-65 Celine M. Laffont Application of a new method for multivariate analysis of longitudinal ordinal data testing robenacoxib in canine osteoarthritis Thursday 15:00-16:30 |
IV-66 Cédric Laouenan Modeling hepatitis C viral kinetics to compare antiviral potencies of two protease inhibitors: a simulation study under real conditions of use Thursday 15:00-16:30 |
IV-67 Anna Largajolli Visual Predictive Check (VPC) in models with forcing functions Thursday 15:00-16:30 |
IV-68 Christian Laveille Use of an exposure-response model for lacosamide in adults with partial onset seizures to analyze preliminary data from a pediatric trial Thursday 15:00-16:30 |
IV-69 Marc Lavielle On the use of stochastic differential mixed effects models for modeling inter occasion variability. Models and methods Thursday 15:00-16:30 |